Patents by Inventor Christer Lars Bertil Wingren
Christer Lars Bertil Wingren has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220214344Abstract: The present invention relates to a method for determining the presence of pancreatic cancer in an individual comprising or consisting of the steps of: (a) providing a sample to be tested from the individual, and (b) determining a biomarker signature of the test sample by measuring the expression in the test sample of one or more biomarkers selected from the group defined in Table A, wherein the expression in the test sample of one or more biomarkers selected from the group defined in Table A is indicative of the individual having pancreatic cancer. The invention also comprises arrays and kits of parts for use in the method of the invention.Type: ApplicationFiled: March 25, 2022Publication date: July 7, 2022Inventors: Carl Arne Krister Borrebaeck, Christer Lars Bertil Wingren
-
Publication number: 20210325395Abstract: The present invention relates to a method for determining the locality and/or presence of pancreatic cancer in an individual comprising or consisting of the steps of: (a) providing a sample to be tested from the individual, and (b) determining a biomarker signature of the test sample by measuring the expression in the test sample of one or more biomarkers selected from the group defined in Table A, wherein the expression in the test sample of one or more biomarkers selected from the group defined in Table A is indicative of the locality and/or presence of pancreatic cancer in the individual. The invention also comprises arrays and kits of parts for use in the method of the invention.Type: ApplicationFiled: September 22, 2016Publication date: October 21, 2021Applicant: Immunovia ABInventors: Carl Arne Krister Borrebaeck, Christer Lars Bertil Wingren
-
Patent number: 10564163Abstract: The present invention provides methods and arrays for the prognosis and treatment of breast cancer in a subject. In a particular embodiment, the methods comprise the steps of: (a) providing a first proteome sample from the subject; (b) measuring in the first proteome sample the amount of two or more biomarkers selected from the group of biomarkers listed in Table 1; (c) providing an additional proteome sample from the subject; (d) measuring in the additional proteome sample the amount of the two or more biomarkers selected from the group of biomarkers listed in Table 1 measured in step (b); (e) determining the difference between the amount of the one or more biomarkers in the first and additional proteome samples; (f) calculating biomarker velocities; (g) determining a risk of recurrence of breast cancer; and (h) treating the subject.Type: GrantFiled: January 18, 2018Date of Patent: February 18, 2020Assignee: IMMUNOVIA ABInventors: Carl Arne Krister Borrebaeck, Christer Lars Bertil Wingren
-
Publication number: 20190128891Abstract: The present invention relates to a method for determining the presence of pancreatic cancer in an individual comprising or consisting of the steps of: (a) providing a sample to be tested from an individual, and (b) determining a biomarker signature of the test sample by measuring the expression in the test sample of one or more biomarkers selected from the group defined in Table A is indicative of the individual having pancreatic cancer. The invention also comprises arrays and kits of parts for use in the method of the invention.Type: ApplicationFiled: October 16, 2018Publication date: May 2, 2019Inventors: Carl Arne Krister Borrebaeck, Christer Lars Bertil Wingren
-
Publication number: 20180313852Abstract: The present invention provides a method for the prognosis of breast cancer in a subject comprising the steps of: (a) providing a first proteome sample from the subject; (b) measuring in the first proteome sample the amount of one or more biomarkers selected from the group of biomarkers listed in Table 1; (c) providing an additional (e.g. a second) proteome sample from the subject; (d) measuring in the additional proteome sample the amount of the one or more biomarkers selected from the group of biomarkers listed in Table 1 measured in step (b); and (e) determining the difference between the amount of the one or more biomarkers in the first and additional proteome samples; wherein the first proteome sample and additional proteome sample are representative of the proteome composition of the subject on different days, and wherein the difference between the amount of the one or more biomarkers in the first and additional (e.g.Type: ApplicationFiled: January 18, 2018Publication date: November 1, 2018Inventors: Carl Arne Krister Borrebaeck, Christer Lars Bertil Wingren
-
Publication number: 20180284120Abstract: The present invention provides a method for determining a breast cancer-associated disease state comprising the steps of: a) providing a sample to be tested; and b) determining a biomarker signature of the test sample by measuring the presence and/or amount in the test sample of one or more biomarker selected from the group defined in Table 1; wherein the presence and/or amount in the test sample of the one or more biomarker selected from the group defined in Table 1 is indicative of the breast cancer-associated disease state. The invention further provides arrays and kits fir use in the same.Type: ApplicationFiled: December 27, 2017Publication date: October 4, 2018Inventors: Carl Arne Krister Borrebaeck, Christer Lars Bertil Wingren
-
Patent number: 10048265Abstract: The invention provides a method for determining prostate cancer-associated disease state in an individual comprising or consisting of the steps of: (a) providing a sample to be tested from the individual; and (b) determining a biomarker signature of the test sample by measuring the expression in the test sample of one or more biomarkers selected from the group defined in Table 1; wherein the expression in the test sample of the one or more biomarkers selected from the group defined in Table 1 is indicative of one or more prostate cancer-associated disease state in the individual. The invention also provides arrays and kits for use in the same.Type: GrantFiled: April 2, 2014Date of Patent: August 14, 2018Assignee: Immunovia ABInventors: Carl Arne Krister Borrebaeck, Christer Lars Bertil Wingren
-
Publication number: 20170192004Abstract: The present invention provides a method for diagnosing breast cancer comprising or consisting of the steps of (a) providing a sample to be tested; and (b) determining a biomarker signature of the test sample by measuring the presence and/or amount in the test sample of one or more biomarker selected from the group defined in Table A(i) and/or Table A(ii); wherein the presence and/or amount in the test sample of the one or more biomarker selected from the group defined in Table A(i) and/or Table A(ii) is indicative of the presence of breast cancer cells in the individual, corresponding uses, methods of treating breast cancer, together with arrays and kits for use in the same.Type: ApplicationFiled: June 9, 2015Publication date: July 6, 2017Inventors: Carl Arne Krister Borrebaeck, Christer Lars Bertil Wingren
-
Publication number: 20160252513Abstract: The present invention relates to a method for determining the presence of pancreatic cancer in an individual comprising or consisting of the steps of: (a) providing a sample to be tested from an individual, and (b) determining a biomarker signature of the test sample by measuring the expression in the test sample of one or more biomarkers selected from the group defined in Table A is indicative of the individual having pancreatic cancer. The invention also comprises arrays and kits of parts for use in the method of the invention.Type: ApplicationFiled: November 11, 2014Publication date: September 1, 2016Inventors: Carl Arne Krister Borrebaeck, Christer Lars Bertil Wingren
-
Publication number: 20160041173Abstract: The invention provides a method for determining prostate cancer-associated disease state in an individual comprising or consisting of the steps of: (a) providing a sample to be tested from the individual; and (b) determining a biomarker signature of the test sample by measuring the expression in the test sample of one or more biomarkers selected from the group defined in Table 1; wherein the expression in the test sample of the one or more biomarkers selected from the group defined in Table 1 is indicative of one or more prostate cancer-associated disease state in the individual. The invention also provides arrays and kits for use in the same.Type: ApplicationFiled: April 2, 2014Publication date: February 11, 2016Applicant: Immunovia ABInventors: Carl Arne Krister Borrebaeck, Christer Lars Bertil Wingren
-
Publication number: 20150057177Abstract: The present invention provides a method for determining a breast cancer-associated disease state comprising the steps of: a) providing a sample to be tested; and b) determining a biomarker signature of the test sample by measuring the presence and/or amount in the test sample of one or more biomarker selected from the group defined in Table 1; wherein the presence and/or amount in the test sample of the one or more biomarker selected from the group defined in Table 1 is indicative of the breast cancer-associated disease state. The invention further provides arrays and kits fir use in the same.Type: ApplicationFiled: April 10, 2013Publication date: February 26, 2015Inventors: Carl Arne Krister Borrebaeck, Christer Lars Bertil Wingren
-
Publication number: 20130143760Abstract: The present invention provides a method for the prognosis of breast cancer in a subject comprising the steps of: (a) providing a first proteome sample from the subject; (b) measuring in the first proteome sample the amount of one or more biomarkers selected from the group of biomarkers listed in Table 1; (c) providing an additional (e.g. a second) proteome sample from the subject; (d) measuring in the additional proteome sample the amount of the one or more biomarkers selected from the group of biomarkers listed in Table 1 measured in step (b); and (e) determining the difference between the amount of the one or more biomarkers in the first and additional proteome samples; wherein the first proteome sample and additional proteome sample are representative of the proteome composition of the subject on different days, and wherein the difference between the amount of the one or more biomarkers in the first and additional (e.g.Type: ApplicationFiled: June 9, 2011Publication date: June 6, 2013Applicant: Immunovia ABInventors: Carl Arne Krister Borrebaeck, Christer Lars Bertil Wingren